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K.-C. Sung et al.combination versus telmisartan/amlodipine (TA) com-
bination in patients with essential hypertension that
did not respond appropriately to 4-week treatment
with TA.
Methods: All patients who met the inclusion criteria
received TA (40/5 mg) during a 4-week run-in period
(period 1). Patients who met the criteria for essential
hypertension (mean sitting systolic blood pressure
[MSSBP], ≥140 ando200 mm Hg, or ≥130 ando200
mm Hg in those with diabetes mellitus or chronic
kidney disease) after period 1 were randomly assigned
to receive TA 40/5 mg þ hydrochlorothiazide 12.5 mg
(test group) or TA only (control group). The test and
control drugs were administered in each group for 2
weeks (period 2). Patients who completed period 2
underwent 6-week treatment (period 3) with a TAH
and TA dose twice that in period 2. The primary end
point was the change in MSSBP at week 8 of treatment.
Secondary end points were the change in MSSBP at
week 2 and MS diastolic BP, BP control rate, and BP
response rate at weeks 2 and 8. Treatment tolerability
was assessed based on adverse events (AEs), laboratory
evaluations (chemistry, hematology, and urinalysis),
12-lead ECG, and physical examination including vital
sign measurements.
Findings: We randomized 310 patients to the treat-
ment groups. The mean (SD) ages of the TAH and TA
groups were 62.0 (10.8) and 63.4 (10.4) years, respec-
tively. The least squares mean change in MSSBP was
signiﬁcantly greater in the TAH group than in the
TA group after 8 weeks (–18.7 vs –12.2 mm Hg;
P o 0.001). Similar results were obtained on changes
in MSSBP after 2 weeks and changes in sitting diastolic
BP, BP control rate, and BP response rate at weeks 2
and 8 compared with the respective baseline values.
The prevalences of treatment-emergent AEs (29.0% vs
16.3%; P ¼ 0.008) and adverse drug reactions (20.0%
vs 10.5%; P ¼ 0.020) were signiﬁcantly greater in the
TAH group than in the TA group. Most treatment-
emergent AEs were mild or moderate; none were
severe. The most frequently reported AEs were dizzi-
ness and headache.
Implication: TAH triple therapy was more effective
than was TA double therapy in reducing BP in these
patients in Korea with essential hypertension that did
not adequately respond to TA. ClinicalTrials.gov
identiﬁer: NCT02738632. (Clin Ther. 2018;40:50–
63) & 2018 The Authors. Published by Elsevier HS
Journals, Inc.January 2018Key words: amlodipine, blood pressure control,
hydrochlorothiazide, hypertension, telmisartan, triple
combination.INTRODUCTION
According to the Korean National Health and Nu-
trition Examination Survey (KNHANES), the preva-
lence of hypertension in adults aged 430 years was
27.9% (men, 32.7%; women, 23.1%) in 2015.
Hypertension is closely related to cerebrovascular
and cardiovascular diseases, which are the most
frequent causes of death among adults; thus, the
prevention and management of hypertension greatly
impact public health.1,2
Blood pressure (BP) management and the treatment
of hypertension and can signiﬁcantly reduce the risk
for cardiovascular disease.3,4 It has been suggested
that, in hypertensive patients, the BP-lowering effect of
combination therapy is greater than that of a dose
increase in monotherapy.5,6 The use of a combination
of various antihypertensive agents has been shown to
have signiﬁcantly positive effects on BP control and
the prevention of cardiovascular events in hyperten-
sive patients.5,6
According to the 8th Joint National Committee's
guideline on hypertension,7 "In the general nonblack
population, including those with diabetes, initial
antihypertensive treatment should include a thiazide-
type diuretic, calcium channel blocker (CCB),
angiotensin-converting enzyme inhibitor (ACEI), or
angiotensin receptor blocker (ARB). If goal BP is not
reached within a month of treatment, increase the dose
of the initial drug or add a second drug from one of the
classes (thiazide-type diuretic, CCB, ACEI, or ARB)."7
The European Society of Cardiology recommends
initiating a low-dose combination therapy prior to
single-dose treatments of hypertension.8 Additionally,
the guideline from the British Hypertension Society and
the National Clinical Guideline Center recommends
3-drug combinations of an ACEI or ARB, a calcium
antagonist, and a thiazide diuretic in cases in which a
2-drug combination does not yield effective BP control.9,10
DM and chronic kidney disease (CKD) are impor-
tant causes of cardiovascular disease owing to their
associations with hypertension, and because BP con-
trol is often difﬁcult in practice, combination therapy
might be useful in patients with these conditions.51
Clinical TherapeuticsCombination therapy with an ARB and a calcium
antagonist is more effective for BP control and
cardiovascular disease prevention than is monother-
apy.11–13 The BP-lowering effect of thiazide-type
diuretics is enhanced by combined therapy with
β-blockers, ACEIs, ARBs, and dihydropyridine calcium
antagonists. Studies have shown that combined therapy
using an ARB and a thiazide diuretic improved com-
pliance and markedly reduced mean BP.14
Combinations of telmisartan/amlodipine and telmi-
sartan/hydrochlorothiazide have been recognized as
well tolerated11,15,16 and have been approved for use
in Korea. Additionally, no drug interactions have been
reported to occur when amlodipine and hydrochlor-
othiazide are coadministered. Therefore, it is expected
that a 3-drug combination such as telmisartan/amlo-
dipine þ hydrochlorothiazide (TAH) would be well
tolerated. Toxicity test results from a study in rats
showed that toxicity reactions to treatment with
3-drug combinations were similar to those observed
when the agents were administered individually.15
A clinical trial conducted in Japan demonstrated that
TAH was more effective and well tolerated than was a
telmisartan/amlodipine (TA) combination.17 However,
the tolerability and efﬁcacy of a 3-agent combination
have not been fully tested in Korea. In the present
study, we evaluated the efﬁcacy and tolerability of
TAH versus TA combination therapy in patients with
essential hypertension that was not responding
appropriately to TA combination therapy.PATIENTS AND METHODS
Study Participants
At screening (visit 1), patients in Korea who were
aged ≥19 years and had uncontrolled hypertension
(deﬁned as mean sitting systolic [MSS] BP of ≥140
and o200 mm Hg, or ≥130 and o200 mm Hg in
patients with DM or CKD [deﬁned as a baseline
creatinine clearance of ≥30 and ≤60 mL/min] while
taking antihypertensive agents, or ≥160 and o200
mm Hg off-treatment for at least 4 weeks) were
eligible for the study.
Patients with any of the following criteria were
excluded from the study: severe heart failure (New
York Heart Association class III or IV), unstable
angina, myocardial infarction, or valvular heart dis-
ease diagnosed within the previous 6 months; severe
atrial ﬁbrillation, atrial ﬂutter, ventricular tachycardia52or severe arrhythmia, or cerebral infarction occurring
within the previous 6 months; severe cerebrovascular
disorder with a history of cerebrovascular disease,
type 1 DM, uncontrolled type 2 DM (glycosylated
hemoglobin ≥9%), or moderate or malignant retin-
opathy occurring within the previous 6 months; serum
creatinine of 42 mg/dL; a history of drug or alcohol
dependence within the previous 6 months; a surgical
or medical condition that may have signiﬁcantly
affected the pharmacokinetic properties (absorption,
distribution, metabolism, or excretion) of the inves-
tigational products (IPs; telmisartan, amlodipine, or
hydrochlorothiazide); severe hypersensitivity to any of
the IPs; sulfonamide hypersensitivity; anuria, hyper-
calcemia, or low sodium/hypokalemia; Addison dis-
ease and galactose intolerance; genetic anomaly (eg,
Lapp lactose dehydrogenase deﬁciency or glucose–
galactose uptake disorder); chronic inﬂammatory dis-
ease requiring continuous anti-inﬂammatory therapy;
an acute inﬂammatory condition that would have
made it impossible to join the study in the opinion
of an investigator; or a history of malignant tumor,
including leukemia or lymphoma, within the previous
5 years. Patients whose ﬁrst and second BP measure-
ments varied during visit 1, who had a difference in
MSSBP of ≥20 mm Hg or in MS diastolic BP (DBP) of
≥10 mm Hg, or who had an MSDBP of ≥120 mm Hg
at visit 1 or 2 were also excluded from the study. In
addition, patients who had been administered other
IPs within 30 days prior to the present clinical study,
those who took other antihypertensive or anticonvul-
sant drugs during the clinical trial period, and those
who were pregnant/breast-feeding/possibly pregnant
or not using an appropriate contraceptive method
were excluded from the study.
During the 4-week (the duration of response to
hypertension medication) run-in period (period 1),
each patient was administered 1 tablet of TA (40/5
mg) daily. Patients with uncontrolled hypertension
after 4 weeks despite TA treatment were randomly
assigned to receive TAH or TA treatment (visit 2,
week 0, baseline).
Study Design and Procedures
This 8-week, Phase III, multicenter, randomized,
double-blind study was conducted in outpatients at 28
clinical sites in the Republic of Korea. The ﬁrst patient
enrollment occurred in June 2015, and the last patient
completed the trial in November 2016. The studyVolume 40 Number 1
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Figure 1. Study design. H ¼ hydrochlorothiazide; TA ¼ telmisartan/amlodipine.
K.-C. Sung et al.protocol was approved by the institutional review
board at each institution, and the study was per-
formed in compliance with the Declaration of Hel-
sinki, the Korean Good Clinical Practice guideline,
and the standard operating procedures of Ildong
Pharmaceutical Co., Ltd. (Seoul, Korea). All of the
patients provided written informed consent at screen-
ing before undergoing any procedures. IPs were
provided free of charge to patients. In addition,
transportation reimbursements were approved by the
institutional review board at each institution.
The study aimed to compare the efﬁcacy and
tolerability of TAH combination therapy with those
of TA combination treatment after an 8-week treat-
ment period in patients with high BP that did not
respond adequately to 4-week treatment with TA 40/5
mg (Figure 1).
Patients who were eligible for screening by the
clinician at visit 1 (week –4) were administered 1
tablet of TA 40/5 mg* once daily for 4 weeks during
period 1. After period 1, at visit 2 (week 0, baseline),
patients with uncontrolled hypertension despite
treatment were randomly assigned to the TAH
group or the TA group at a ratio of 1:1 and were
administered the corresponding IP once daily for 2
weeks (period 2; TAH group, 1 tablet of TA 40/5 mg
þ hydrochlorothiazide 12.5 mg†; TA group, 1 tablet
of TA 40/5 mg þ hydrochlorothiazide-matching
placebo.‡ The randomization sequence generated
using computer software was used for constructing a*Trademark: Twynsta (Boehringer Ingelheim, Seoul, Korea).
†Trademark: Hydrochlorothiazide Towa (Towa Pharmaceutical
Co, Ltd, Osaka, Japan).
‡Produced by Ildong Pharmaceutical Co, Ltd (Seoul, Korea).
January 2018random block of 2 or 4, stratiﬁed by the participating
center. The patients were assigned to the groups using
an interactive Web-response system.
Patients with uncontrolled hypertension at visit 2
were switched to a standard therapy as determined by
the investigators. At visit 3 (week 2), patients returned
to the clinical institution and were initiated on a
double dose of IPs for 6 weeks (period 3). At visit 4
(week 4), the patients did not visit the institution, and
the investigators checked patients' health status and
adherence to medication by telephone contact. At visit
5 (week 8), patients who had completed the treatment
completed the clinical trial, which lasted a total of
12 weeks.
To ensure double-blinding, the inactive hydrochlor-
othiazide placebo was manufactured in a tablet for-
mulation with an appearance (color, shape, and size)
and label identical to those of the active hydrochlor-
othiazide, so that no differences could be detected
visually.
BP was measured by the same investigator when
possible, using an electronic sphygmomanometer
(HEM-7080IC; Omron Healthcare, Tokyo, Japan)
supplied by the sponsor. A standardized cuff of an
appropriate size was used, although the bladder was
80% longer and 40% wider than required when
wrapped around the arm. This was done to ensure
that the measurements were taken from arms without
functional or anatomic abnormalities. After measure-
ment of the BP using both arms at visit 1, the arm
showing a higher BP value was used for subsequent
measurements. However, if subsequent measurements
from the same arm were not possible, the cause was
recorded, and the BP was measured in the other arm.
Patients were instructed to avoid caffeine intake,53
Clinical Therapeuticsexercise, and smoking for at least 30 minutes prior to
each BP measurement. During the sitting BP measure-
ment, patients sat in a chair with back support, and
the arm was placed at heart level. Patients rested in a
sitting position for 5 minutes or more, after which BP
was measured in the upper arm. BP was measured at
the same time (morning). The cuff was released
completely between measurements. BP was measured
3 times at intervals of 2 minutes or more, and the
MSSBP and MSDBP values were calculated.
During the clinical trial, patients whose MSSBP
value was4200 mm Hg or whose MSDBP value was
4120 mm Hg at any visit were withdrawn from the
study. In addition, patients with signs or symptoms of
hypotension, who had an MSSBP ofo100 mm Hg, or
an MSDBP of o60 mm Hg, at any visit during the
study period were withdrawn at the investigator's
discretion and treated medically by the investigator.
For standardization, the staff at the research in-
stitutes involved in this clinical study were trained in
the protocol, and suggested study guidelines were
provided, as was regular monitoring by PharmaCRO
Inc (Seoul, Korea).
Efficacy Variables
The primary efﬁcacy assessment variable was the
least-squares (LS) mean change from baseline in SBP
after 8 weeks of treatment (triple therapy vs double
therapy). Secondary efﬁcacy assessment variables were
as follows: LS mean change in SBP after 2 weeks, and
LS mean changes from baseline in DBP, rate of BP
control (SBP/ DBPo140/o90 mm Hg, oro130/o80
mm Hg in patients with DM or CKD), and rate of BP
response (reduction in SBP of 420 mm Hg or in DBP
of410 mm Hg) after 2 and 8 weeks of treatment. For
missing values, the last-observation-carried-forward
approach was used. In addition, subgroup analyses
were performed to assess the rate of BP control after 2
and 8 weeks of treatment in patients with and without
DM/CKD.
Tolerability Assessment
The tolerability assessment variables were treat-
ment-emergent adverse events (TEAEs) after visit
2 and laboratory test results (general blood tests,
serum biochemistry tests, and urinalysis), vital sign
measurements (pulse and weight), and ECG. General
blood testing, serum biochemistry testing, urinalysis,
and vital sign measurements were performed at weeks54–4, 0, 2, and 8. ECG was evaluated at visits 1 and 4
(weeks –4 and 8). The severity and causality of the
AEs were evaluated based on the opinions of the study
investigators.Statistical Analysis
The sample size was calculated using 95% power at
a 1-sided superiority signiﬁcance level of 2.5% to
detect statistical signiﬁcance in between-treatment
differences in mean changes from baseline in SBP,
assuming a mean reduction of 5.7 mm Hg and an SD
of 12.6 mm Hg.18,19 Thus, a sample size of 254
patients who completed the study was planned for this
clinical trial, assuming that 150 patients were to be
randomized into each treatment group (N = 300,
considering a 15% dropout rate). Efﬁcacy analyses
were carried out using a full analysis set (based on an
intent-to-treat principle) and included all randomly
assigned patients who took IPs at least once after
randomization and had a mean SBP measured at least
once before the trial ended and after IP administra-
tion. Tolerability analyses were carried out using a
tolerability set that included patients who took IPs at
least once after randomization and whose tolerability-
related data were veriﬁed at least twice via telephone
communication or clinic visits between IP intake and
the end of the trial.
To compare the mean changes with triple therapy
versus double therapy, an ANCOVA model was used,
with treatment as a factor and baseline values as
covariates. For each comparison, LS mean change (SE)
and P value were estimated from the ANCOVA
model. The BP control and response rates in each
treatment group were summarized and analyzed using
the Pearson χ2 test or the Fisher exact test.
For the assessment of adverse reactions, the prev-
alences and percentages of patients who experienced
TEAEs, ADRs, severe adverse reactions, and adverse
reactions that resulted in permanent discontinuation
of IPs after randomization were summarized. We also
analyzed the severity of AEs and the likelihood that
they were related to the IPs. For TEAEs that occurred
in41% of patients after randomization, the preferred
term designated in the Medical Dictionary for Regu-
latory Activities (version 19.0) was used, and the
prevalence was recorded. The frequencies of AEs by
system organ class and preferred term per treatment
group, as well as their severity, were recorded, as wereVolume 40 Number 1
K.-C. Sung et al.severe adverse reactions that necessitated permanent
discontinuation of IPs.
To test differences in the frequencies of AEs likely
resulting from triple or double therapy, the Pearson χ2
test or Fisher exact test was conducted. All statistical
analyses were performed using SAS software version
9.3 or higher (SAS Institute Inc, Cary, North Carolina).RESULTS
Patient Disposition, Demographic
Characteristics, and Baseline Variables
A total of 567 patients with essential hypertension
were screened; 257 were ineligible for the study. The
primary reason for exclusion before randomization
was the failure to satisfy all inclusion criteria or
fulﬁllment of the exclusion criteria at visit 1 (68
[12.0%]) and visit 2 (159 [28.0%]). Of the 310
enrolled patients, 155 were randomized to receive
TAH; 155, TA (Figure 2). During the double-blindScreening
(n = 567)
(n = 310)
(n = 155)
TAH
Tot
Discontinued (n = 17)
Adverse events (3)
Withdrawal of consent (8)
Protocol violation (3)
Others (3)
Completed
(n = 138 [89.0%])
Randomized
Figure 2. Patient disposition. S/F ¼ screening failure;
amlodipine/hydrochlorothiazide.
January 2018treatment phase, 17 (11.0%) and 11 (7.1%) patients in
the TAH and TA groups, respectively, dropped out.
The most common reasons for discontinuation of TAH
were the withdrawal of consent (5.2%) and AEs,
protocol violation, and other factors (1.9% each).
The most common reasons for discontinuation of TA
were the withdrawal of consent (2.6%), AEs (1.9%),
protocol violation (1.3%), and other factors (1.3%).
For the efﬁcacy analysis there were 151 and 153
patients in the TAH and TA groups, and for the
tolerability evaluation, there were 155 and 153
patients in the TAH and TA groups. Four patients
who did not undergo the primary efﬁcacy evaluation in
the TAH group were excluded from the efﬁcacy
analysis, and 2 patients in the TA group who were
participating at multiple study sites were excluded from
the efﬁcacy analysis and tolerability evaluation.
The mean (SD) age of the randomized patients was
62.8 (10.6) years; 79% of the patients were men
(76.8%, TAH group; 81.3%, TA group). The mean(n = 155)
TA
al S/F (n = 257)
at Visit 1 (n = 75)
Failure to meet eligibility requirements (68)
Failure to meet eligibility requirements (159)
Withdrawal of consent (6)
Withdrawal of consent (13)
Completed
(n = 144 [92.9%])
Discontinued (n = 11)
Adverse events (3)
Withdrawal of consent (4)
Protocol violation (2)
Others (2)
Others (1)
Others (10)
at Visit 2 (n = 182)
TA ¼ telmisartan/amlodipine; TAH ¼ telmisartan/
55
Table I. Baseline demographic and clinical characteristics of randomized patients.
Characteristic TAH (n ¼ 155) TA (n ¼ 155) All Patients (N ¼ 310) P*
Age, mean (SD), y 62.0 (10.8) 63.4 (10.4) 62.8 (10.6) 0.187
Sex, no. (%) 0.329
Male 119 (76.8) 126 (81.3) 245 (79.0) –
Female 36 (23.2) 29 (18.7) 65 (21.0) –
Anthropometrics, mean (SD)
Weight, kg 74.2 (13.4) 72 (10.9) 73.1 (12.3) 0.119
Height, cm 166.8 (7.6) 165.5 (7.8) 166.1 (7.8) 0.146
BMI, kg/m2 26.6 (3.6) 26.3 (3.3) 26.4 (3.5) 0.426
Vital signs, mean (SD)
Baseline sitting SBP,† mm Hg 153.7 (10.7) 152.6 (10.4) 153.2 (10.6) 0.357
Baseline sitting DBP,† mm Hg 90.1 (10.1) 88.8 (10.7) 89.5 (10.4) 0.278
Heart rate, beats/min 73.9 (10.8) 73.5 (12.5) 73.7 (11.7) 0.789
Comorbidity, no. (%)
DM 33 (21.9) 46 (29.7) 79 (25.5) 0.090
CKD‡ 21 (13.5) 25 (16.1) 46 (14.8) 0.523
DM or CKD‡ 50 (32.3) 62 (40.0) 112 (36.1) 0.156
BMI ¼ body mass index; CKD ¼ chronic kidney disease; DBP ¼ diastolic blood pressure; DM ¼ diabetes mellitus; SBP ¼
systolic blood pressure; TA ¼ telmisartan plus amlodipine; TAH ¼ telmisartan plus amlodipine plus hydrochlorothiazide.
⁎Using independent t test for continuous variables and Pearson χ2 test for categorical variables.
†Baseline BP was deﬁned as the mean of measurements from the randomization visit.
‡Deﬁned as a baseline creatinine clearance rate of ≥30 and ≤60 mL/min.
Clinical Therapeuticsbody mass index was 26.4 (3.5) kg/m2, and the mean
heart rate was 73.7 (11.7) beats/min. The numbers of
patients with DM and CKD were 79 (25.5%) and 46
(14.8%), respectively. The mean SBP values at base-
line in the TAH and TA groups were 153.7 (10.7) and
152.6 (10.4) mm Hg; mean DBP values were 90.1
(10.1) and 88.8 (10.7) mm Hg; SBP/DBP values in
both groups were therefore similar. Demographic and
clinical characteristics at baseline did not differ sig-
niﬁcantly between the TAH and TA groups (Table I).
Efficacy
TAH caused a signiﬁcantly greater LS mean reduc-
tion in SBP at week 8 than TA did (Figure 3). The LS
mean (SE) changes in SBP were –18.7 (1.1) and –12.2
(1.1) mm Hg in the TAH and TA groups, respectively
(Po 0.001). Treatment with TAH was associated with
a signiﬁcant LS mean reduction in DBP at week 8,
whereas treatment with TA was not (–9.3 [0.6] vs –7.0
[0.6] mm Hg; P ¼ 0.013). In both treatment groups, a
BP-lowering effect was observed after 2 weeks. LS
mean reductions in SBP and DBP in the TAH group56were signiﬁcantly less than were those in the TA group
(SBP, P o 0.001; DBP, P ¼ 0.006). MSSBP and
MSDBP from weeks 2 to 8 are illustrated in Figure 4.
BP control rates were 31.8% (TAH) and 13.8%
(TA) at week 2 and 52.3% (TAH) and 24.8% (TA) at
week 8 (both, P o 0.001) (Figure 5). BP response
rates were 33.8% (TAH) and 21.1% (TA) at week 2
(P ¼ 0.013) and 56.3% (TAH) and 34.6% (TA) at
week 8 (P o 0.001) (Table II).
Subanalysis of the patients after 2 and 8 weeks of
treatment showed a signiﬁcantly greater BP control
rate among patients without DM or CKD in the TAH
group than in the TA group (37.9% vs 16.5% at week
2; 62.1% vs 33.7% at week 8; both, P o 0.001). In
the TAH group, patients without DM or CKD
showed a signiﬁcantly greater BP control rate after
the treatments at weeks 2 and 8 than did patients with
DM or CKD. However, in the TA group, patients
without DM or CKD showed a signiﬁcantly greater
BP control rate compared with patients with DM or
CKD after treatment week 8 only (33.7% vs 11.5%;
P ¼ 0.002) (Figure 5).Volume 40 Number 1
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We assessed the tolerability proﬁles of the treat-
ments in 308 patients (TAH group, 155; TA group,
153) (Table III). The prevalence of TEAEs was
signiﬁcantly greater in the TAH group than in the
TA group (29.0% vs 16.3%; P ¼ 0.008). TEAEs wereA
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January 2018mild (n ¼ 58) or moderate (n ¼ 13), and none were
severe. The most frequently reported AEs were
dizziness (6.5%) and headache (2.6%). Dizziness
occurred more frequently in the TAH group (11.0%)
than in the TA group (2.0%) (P ¼ 0.001). Serious
TEAEs that occurred in the TAH group were back
pain and intervertebral disc protrusion (n ¼ 1 each).
Causality relationships between these TEAEs and
the treatments were assessed as "unlikely" by an
investigator. One case of syncope was reported in
the TA group, and the causality assessment was ruled
"certain." The prevalence of ADRs was signiﬁcantly
greater in the TAH group than in the TA group
(20.0% vs 10.5%; P ¼ 0.020). There were no
differences in the prevalences of TEAEs and ADRs
between the 2 groups in period 2 (prior to period 3,
in which the dose was double that of period 2).
The prevalences of TEAEs were 9.7% and 9.8% in
the TAH and TA groups, respectively, in period 2
(P ¼ 0.970). The prevalences of ADRs were 5.2%
and 4.6% in the TAH and TA groups in period 2
(P ¼ 0.811). The prevalences of TEAEs and ADRs
were signiﬁcantly greater in the TAH group than in
the TA group in period 3. The prevalences of TEAEs
were 20.0% and 7.8% in the TAH and TA groups,
respectively, in period 3 (P ¼ 0.002). The prevalences
of ADRs were 14.8% and 6.5% in the TAH and TA
groups in period 3 (P ¼ 0.019) (Table IV).B
M
ea
n 
si
tt
in
g 
D
B
P 
(m
m
 H
g)
Time Point
Week 8Baseline
70.0
75.0
80.0
85.0
90.0
95.0
100.0 TAH
TA
90.1
84.8
80.6
88.9
86.2
82.1
Week 2
and diastolic blood pressure (DBP; B) after 2 and 8
ine þ hydrochlorothiazide (TAH) or telmisartan/
57
100
90
80
70
C
on
tr
ol
 r
at
e 
of
 s
itt
in
g 
B
P 
(%
)
50
60
40
20
30 31.8
13.8
52.3
24.8
18.8
9.8
31.3
11.5
37.9
16.5
62.1
33.7
18.2
11.1 11.1
30.3
35.6
14.9
30.6
58.5
55.3
31.6 31.6 31.8
4.0
15.8
28.1
10
Week 2
n = 304
(TAH, 151; TA, 153)
Total
n = 109 n = 195 n = 78 n = 226 n = 44 n = 260
(TAH, 48; TA, 61) (TAH, 103; TA, 92) (TAH, 33; TA, 45) (TAH, 118; TA, 108) (TAH, 19; TA, 25) (TAH, 132; TA, 128)
With DM or CKD Without DM or CKD Without CKDWith CKDWithout DM With DM
Week 2Week 8 Week 8 Week 2 Week 8 Week 2 Week 8 Week 2 Week 2 Week 2Week 8 Week 8 Week 8
0
P = 0.019
P = 0.002 P = 0.011 P = 0.033
TAH
TA
P = 0.004P = 0.001
† †
8.0
‡ 
‡ 
‡ 
‡ 
‡ 
‡ 
‡
‡
‡
Figure 5. Rates of sitting blood pressure (BP) control (o140/o90 mm Hg [or o130/o80 mm Hg in
patients with diabetes mellitus [DM] or chronic kidney disease [CKD; baseline creatinine clearance
≥30 and ≤60 mL/min]) after 2 and 8 weeks of treatment with telmisartan/amlodipine þ
hydrochlorothiazide (TAH) or telmisartan/amlodipine (TA). †Po 0.05 and ‡Po 0.001 versus TA.
Clinical TherapeuticsThree patients in the TAH group dropped out of
the study because of dizziness (n ¼ 2, ADRs) and
intervertebral disc protrusion (n ¼ 1, AEs). The 2
cases of dizziness were ADRs and categorized as
moderate in intensity. The patients who discontinued
the IPs because of dizziness were prescribed the same
antihypertensive drugs they received prior to the trial
and recovered. In the TA group, 3 patients dropped
out of the study because of headache (mild, ADRs),
syncope (moderate, ADRs), and retinal hemorrhage
(moderate, ADRs). The headache and syncope con-
tinued, whereas the retinal hemorrhage improved by
the end of the study. There were no signiﬁcant differ-
ences in permanent discontinuation of the IPs because
of ADRs or AEs between the groups.Table II. Blood pressure response* rate. Data are
given as number (%) of patients.
Visit TAH (n ¼ 151) TA (n ¼ 153) P†
Week 2‡ 51 (33.8) 32 (21.1) 0.013
Week 8 85 (56.3) 53 (34.6) o0.001
TA ¼ telmisartan/amlodipine; TAH ¼ telmisartan/
amlodipine/hydrochlorothiazide.
⁎Deﬁned as a reduction from baseline of ≥20 mm Hg
(sitting systolic blood pressure) or ≥10 mm Hg (sitting
diastolic blood pressure).
†Using Pearson χ2 test.
‡Excluding 1 patient in the TA group with a missing
value.
58Laboratory tests in the TAH group showed that
renal function parameters such as serum creatinine,
blood urea nitrogen, and blood uric acid levels
increased slightly, whereas serum Na, K, and Cl levels
were decreased slightly from their respective baseline
values. These changes were attributed to the diuretic
properties of hydrochlorothiazide. There were no
signiﬁcant changes in laboratory test results in the
TA group (Table V).
Medication Compliance
Both groups exhibited comparable levels of medica-
tion compliance. The mean (SD) medication compliance
rates were 96.5% (12.0%) and 96.9% (6.2%) in the
TAH and TA groups, respectively (data not shown).DISCUSSION
In this study, we investigated the efﬁcacy and toler-
ability of TAH in patients with essential hypertension
that did not respond adequately to TA. A previous
systematic review and meta-analysis of 3- and 2-drug
regimens for treating hypertension found that triple
therapy with an ARB, a CCB, and a diuretic lowered
mean (95% CI) SBP/DBP by 5.2 (4.3–6.1)/3.2 (2.6–3.7)
mm Hg, yielding better results than did dual therapy
with an ARB and a CCB.20 While a direct comparison
with the ﬁndings from our study is difﬁcult, the results
from the 2 studies are in agreement.
One multinational study found that 46.5% of
participants with hypertension were aware of their
condition, and approximately one third of thoseVolume 40 Number 1
Table III. Overview of treatment-emergent adverse events (TEAEs). Data are given as number (%) of patients.
Variable TAH (n ¼ 155) TA (n ¼ 153) All Patients (N ¼ 308) P
Patients with any TEAE 45 (29.0) 25 (16.3) 70 (22.7) 0.008*
Severity 0.522†
Mild 39 (25.2) 19 (12.4) 58 (18.8)
Moderate 7 (4.5) 6 (3.9) 13 (4.2)
Severe 0 0 0
Relationship to IP 0.925†
Deﬁnitely related 2 (1.3) 0 2 (0.7)
Probably related 2 (1.3) 2 (1.3) 4 (1.3)
Possibly related 10 (6.5) 5 (3.3) 15 (4.9)
Probably not related 16 (10.3) 11 (7.2) 27 (8.8)
Deﬁnitely not related 17 (11.0) 10 (6.5) 27 (8.8)
Unknown/nonassessable 1 (0.7) 0 1 (0.3)
Patients with serious TEAEs 2 (1.3)‡ 1 (0.7)§ 3 (1.0) 1.000†
Patients who withdrew because of TEAEs 3 (2.0)‖ 3 (2.0)¶ 6 (2.0) 1.000†
TEAEs occurring in ≥1% patients
Dizziness 17 (11.0) 3 (2.0) 20 (6.5) 0.001*
Headache 4 (2.6) 4 (2.6) 8 (2.6) 1.000†
Nasopharyngitis 3 (2.0) 4 (2.6) 7 (2.3) 0.722†
Constipation 2 (1.3) 3 (2.0) 5 (1.6) 0.683†
Asthenia 2 (1.3) 1 (0.7) 3 (1.0) 1.000†
Edema, peripheral 2 (1.3) 1 (0.7) 3 (1.0) 1.000†
Back pain 2 (1.3) 0 2 (0.7) 0.498†
Cough 2 (1.3) 0 2 (0.7) 0.498†
Nausea 2 (1.3) 0 2 (0.7) 0.498†
Proteinuria 2 (1.3) 0 2 (0.7) 0.498†
IP ¼ investigational product; TA ¼ telmisartan/amlodipine; TAH ¼ telmisartan/amlodipine/hydrochlorothiazide.
⁎Pearson χ2 test.
†Fisher exact test when expected cell counts of o5 comprise 25% or more of a table.
‡Serious TEAEs that occurred in the TAH group were back pain and intervertebral disc protrusion (n ¼ 1 each). Causality
relationships between these TEAEs and the treatments were assessed as "unlikely" by an investigator.
§One serious case of syncope was reported in the TA group, and the causality assessment was assessed as "certain" by an
investigator.
‖Three patients in the TAH group were withdrawn from the study because of dizziness (n ¼ 2, ADRs) and intervertebral disc
protrusion (n ¼ 1, AEs). The 2 cases of dizziness were ADRs and categorized as moderate in intensity. The patients who
discontinued the IPs because of dizziness were prescribed the same antihypertensive drugs they received prior to the trial and
recovered.
¶In the TA group, 3 patients were withdrawn from the study because of headache (mild, ADRs), syncope (moderate, ADRs),
and retinal hemorrhage (moderate, ADRs).
K.-C. Sung et al.treated for hypertension achieved their target BP.21
Clinical trials have shown that adequate BP control
is possible with combinations of up to 4
antihypertensive drugs.22–26 In the present study, the
target BP (o140/o90 mm Hg) was achieved inJanuary 201852.3% of the patients who received TAH and
24.8% of those who received TA. The subanalysis
revealed that in patients with DM/CKD, the target BP
(o130/o80 mm Hg) was more effectively achieved
with TAH than with TA (31.3% vs 11.5%).59
Table IV. Summary of treatment-emergent adverse events (TEAEs) in study periods 2 and 3. Data are given as
number (%) of patients, [number of cases].
Variable TAH (n ¼ 155) TA (n ¼ 153) All Patients (n ¼ 308) P*
TEAEs† 45 (29.0), [68] 25 (16.3), [31] 70 (22.7), [99] 0.008
Period 2 15 (9.7), [24] 15 (9.8), [18] 30 (9.7), [42] 0.970
Period 3 31 (20.0), [42] 12 (7.8), [13] 43 (14.0), [55] 0.002
ADRs‡ 31 (20.0), [46] 16 (10.5), [18] 47 (15.3), [64] 0.020
Period 2 8 (5.2), [15] 7 (4.6), [7] 15 (4.9), [22] 0.811
Period 3 23 (14.8), [30] 10 (6.5), [11] 33 (10.7), [41] 0.019
ADRs ¼ adverse drug reactions; TA ¼ telmisartan/amlodipine; TAH ¼ telmisartan/amlodipine/hydrochlorothiazide.
⁎Pearson χ2 test.
†Excluding 2 patients with missing data in the TAH group.
‡Excluding 1 patient with missing data in the TAH group.
Clinical TherapeuticsWith regard to tolerability, the AEs reported in this
study were mild or moderate in severity. The preva-
lences of AEs/ADRs were greater in the TAH group
than in the TA group. A clinical trial conducted in
Japan comparing TAH and TA found a similar
trend.17
In the present trial, the prevalences of dizziness
were 11.0% and 2.0% in the TAH and TA groups,
respectively. Although there were differences in AEs
between the groups, all AEs were mild and most
resolved without any treatment. In addition, there
were no differences in the prevalences of TEAEs
between the 2 groups in period 2. A previous
forced-titration study found that the prevalence of
dizziness associated with treatment was greater in
patients receiving an amlodipine/valsartan/hydro-
chlorothiazide combination than in patients receiving
an amlodipine/valsartan combination (7.7% vs
2.3%). Other similar ﬁndings have been reported as
well.25,27
Poor medication adherence is associated with a high
mortality rate and a high risk for hospitalization for
speciﬁc cardiovascular diseases.28 According to the
2011 KNHANES, the awareness, management, and
control rates of hypertension among male patients with
hypertension were 58.8%, 51.7%, and 36.9%,
respectively. In addition, according to the 2008
KNHANES, 42% of elderly patients in Korea failed
to observe medication guidelines, with the most
common reason being that they "just forgot"
(81.8%).1 To improve compliance, several60guidelines29–31 recommend the use of combination
medicines. Research has shown that compliance rates
are greater when medications are administered as
combination therapies than when they are administered
as single medicaments.29–31 The results from the
present 3-period study support the clinical efﬁcacy
and tolerability of the 3-drug TAH combination, which
can help in the management of hypertension by
increasing compliance. At TAH doses of 80/10/25 mg
and TA doses of 80/10 mg, the prevalence of dizziness
was greater with TAH treatment; Clinically, there was
more beneﬁt than risk.
There were several limitations to this study. First, the
duration of the study was short. We believe that 8 weeks
may not have been sufﬁcient time to observe the full
beneﬁts of the TAH combination or to determine whether
its beneﬁts decrease over a longer period. In addition, the
number of patients with CKD analyzed was small.
Furthermore, the study did not include patients with
severely impaired kidney function (serum creatinine 42
mg/dL), who may also require combination therapies for
the management of hypertension. In addition, the general-
izability of the data to the global population with hyper-
tension would be difﬁcult because this study was limited
to a population in Korea only.CONCLUSIONS
The TAH combination was effective in lowering BP in
these patients in Korea with essential hypertension that
did not respond adequately to TA. Moreover, TAHVolume 40 Number 1
Table V. Laboratory tests results (renal function). Data are given as mean (SD).
Variables TAH (n ¼ 155) TA (n ¼ 153) P*
SCr, mg/dL
Baseline 0.90 (0.2) 0.93 (0.3) –
Week 8 0.94 (0.3) 0.92 (0.3) o0.001
P† o0.001 0.214 –
BUN, mg/dL
Baseline 15.0 (4.5) 15.9 (5.6) –
Week 8 16.8 (4.8) 16.4 (5.2) 0.006
P† o0.001 0.102 –
Serum uric acid, mg/dL
Baseline 5.5 (1.5) 5.5 (1.7) –
Week 8 6.2 (1.6) 5.5 (1.5) o0.001
P† o0.001 0.757 –
Serum Na, mEq/L
Baseline 140.8 (2.7) 140.7 (2.2) –
Week 8 139.7 (2.6) 140.4 (2.4) 0.006
P† o0.001 0.217 –
Serum K, mEq/L
Baseline 4.3 (0.4) 4.3 (0.4) –
Week 8 4.2 (0.4) 4.3 (0.4) o0.001
P† o0.001 0.808 –
Serum Cl, mEq/L
Baseline 103.9 (2.7) 103.9 (2.5) –
Week 8 102.0 (3.0) 103.9 (2.8) o0.001
P† o0.001 0.777 –
BUN ¼ blood urea nitrogen; SCr ¼ serum creatinine; TA ¼ telmisartan/amlodipine; TAH ¼ telmisartan/amlodipine/
hydrochlorothiazide.
⁎Between-group P, unpaired t test.
†Within-group P, paired t test.
K.-C. Sung et al.was an effective and tolerable antihypertensive drug
combination with a high beneﬁt-to-risk ratio. The
ﬁndings from this study provide supporting informa-
tion for clinicians for choosing a ﬁxed-dose triple
combination over a free-combination of 3 antihyper-
tensives including an ARB, a CCB, and a diuretic.ACKNOWLEDGMENTS
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13
Generalisability 21 Generalisability (external validity, applicability) of the trial
ﬁndings
12
Interpretation 22 Interpretation consistent with results, balancing beneﬁts and
harms, and considering other relevant evidence
11-12
Other information
Registration 23 Registration number and name of trial registry 1-2
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Section/Topic
Item
No Checklist item
Reported
on page No
Protocol 24 Where the full trial protocol can be accessed, if available NA
Funding 25 Sources of funding and other support (such as supply of
drugs), role of funders
13
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for
important clariﬁcations on all the items. If relevant, we also recommend reading CONSORT extensions for cluster
randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and
pragmatic trials. Additional extensions are forthcoming: for those and for up to date references relevant to this checklist,
see www.consort-statement.org.
C O N S O R T
TRANSPARENT REPORTING of TRIALS
CONSORT 2010 Flow Diagram
Assessed for eligibility (n= 567) 
Excluded  (n= 257)
Not meeting inclusion criteria (n= 227) 
Declined to participate (n= 19) 
Other reasons (n= 11) 
Analysed  (n= 155)
Excluded from analysis (give reasons) (n= 0)
Lost to follow-up (give reasons) (n=0) 
Discontinued intervention (give reasons)(n=17)
Allocated to intervention (n= 155) 
Received allocated intervention (n= 155) 
Did not receive allocated intervention (give  
reasons) (n= 0)
Lost to follow-up (give reasons) (n= 0) 
Discontinued intervention (give reasons)(n=11)
Allocated to intervention (n= 155) 
Received allocated intervention (n= 155) 
Did not receive allocated intervention (give 
reasons) (n= 0) 
Analysed  (n= 155) 
Excluded from analysis (give reasons)(n= 0)
Allocation
Analysis
Follow-Up
Randomized (n= 310)
Enrollment
♦
♦
♦
♦
♦
♦ ♦
♦
♦
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